Literature DB >> 24200590

Phylogeny and molecular evolution of the hepatitis C virus.

Paulina Jackowiak1, Karolina Kuls2, Lucyna Budzko1, Anna Mania2, Magdalena Figlerowicz2, Marek Figlerowicz3.   

Abstract

The hepatitis C virus (HCV) is a globally prevalent human pathogen that causes persistent liver infections in most infected individuals. HCV is classified into seven phylogenetically distinct genotypes, which have different geographical distributions and levels of genetic diversity. Some of these genotypes are endemic and highly divergent, whereas others disseminate rapidly on an epidemic scale but display lower variability. HCV phylogeny has an important impact on disease epidemiology and clinical practice because the viral genotype may determine the pathogenesis and severity of the resultant chronic liver disease. In addition, there is a clear association between the HCV genotype and its susceptibility to antiviral treatment. Similarly to other RNA viruses, in a single host, HCV exists as a combination of related but genetically different variants. The whole formation is the actual target of selection exerted by a host organism and antiviral therapeutics. The genetic structure of the viral population is largely shaped by mutations that are constantly introduced during an error-prone replication. However, it appears that genetic recombination may also contribute to this process. This heterogeneous collection of variants has a significant ability to evolve towards the fitness optimum. Interestingly, negative selection, which restricts diversity, emerges as an essential force that drives HCV evolution. It is becoming clear that HCV evolves to become stably adapted to the host environment. In this article we review the HCV phylogeny and molecular evolution in the context of host-virus interactions.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Evolution; HCV; Phylogeny

Mesh:

Year:  2013        PMID: 24200590     DOI: 10.1016/j.meegid.2013.10.021

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  21 in total

1.  Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

Authors:  Evguenia S Svarovskaia; Hadas Dvory-Sobol; Neil Parkin; Christy Hebner; Viktoria Gontcharova; Ross Martin; Wen Ouyang; Bin Han; Simin Xu; Karin Ku; Sophia Chiu; Edward Gane; Ira M Jacobson; David R Nelson; Eric Lawitz; David L Wyles; Neby Bekele; Diana Brainard; William T Symonds; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  Clin Infect Dis       Date:  2014-09-28       Impact factor: 9.079

Review 2.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

Review 3.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches.

Authors:  Ester Badami; Rosalia Busà; Bruno Douradinha; Giovanna Russelli; Vitale Miceli; Alessia Gallo; Giovanni Zito; Pier Giulio Conaldi; Gioacchin Iannolo
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

5.  Conserved RNA secondary structures and long-range interactions in hepatitis C viruses.

Authors:  Markus Fricke; Nadia Dünnes; Margarita Zayas; Ralf Bartenschlager; Michael Niepmann; Manja Marz
Journal:  RNA       Date:  2015-05-11       Impact factor: 4.942

6.  The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.

Authors:  François M J Lamoury; Brendan Jacka; Sofia Bartlett; Rowena A Bull; Arthur Wong; Janaki Amin; Janke Schinkel; Art F Poon; Gail V Matthews; Jason Grebely; Gregory J Dore; Tanya L Applegate
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

7.  Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns.

Authors:  Josefine Ederth; Camilla Jern; Helené Norder; Lars Magnius; Erik Alm; Björg Kleverman Rognsvåg; Carl-Gustaf Sundin; Mia Brytting; Joakim Esbjörnsson; Mattias Mild
Journal:  Infect Ecol Epidemiol       Date:  2016-02-05

8.  Blocking Zika virus vertical transmission.

Authors:  Pinar Mesci; Angela Macia; Spencer M Moore; Sergey A Shiryaev; Antonella Pinto; Chun-Teng Huang; Leon Tejwani; Isabella R Fernandes; Nicole A Suarez; Matthew J Kolar; Sandro Montefusco; Scott C Rosenberg; Roberto H Herai; Fernanda R Cugola; Fabiele B Russo; Nicholas Sheets; Alan Saghatelian; Sujan Shresta; Jeremiah D Momper; Jair L Siqueira-Neto; Kevin D Corbett; Patricia C B Beltrão-Braga; Alexey V Terskikh; Alysson R Muotri
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

9.  Copy number variation of genes involved in the hepatitis C virus-human interactome.

Authors:  Lucyna Budzko; Malgorzata Marcinkowska-Swojak; Paulina Jackowiak; Piotr Kozlowski; Marek Figlerowicz
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

10.  Successful outcome of therapy of acute hepatitis C following sexual and parenteral exposure - report of two cases.

Authors:  Katarzyna Mazur-Melewska; Anna Mania; Pawel Kemnitz; Magdalena Figlerowicz; Wojciech Służewski
Journal:  Clin Exp Hepatol       Date:  2016-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.